Sanofi (SNY)
| Market Cap | 121.63B |
| Revenue (ttm) | 51.60B |
| Net Income (ttm) | 6.00B |
| Shares Out | 2.51B |
| EPS (ttm) | 2.31 |
| PE Ratio | 25.29 |
| Forward PE | 11.14 |
| Dividend | $2.04 (4.20%) |
| Ex-Dividend Date | May 9, 2024 |
| Volume | 2,639,970 |
| Open | 48.85 |
| Previous Close | 49.59 |
| Day's Range | 48.45 - 48.85 |
| 52-Week Range | 42.63 - 55.72 |
| Beta | 0.42 |
| Analysts | Hold |
| Price Target | 55.00 (+13.31%) |
| Earnings Date | Jul 26, 2024 |
About SNY
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric ... [Read more]
Financial Performance
In 2023, Sanofi's revenue was 46.44 billion, an increase of 2.32% compared to the previous year's 45.39 billion. Earnings were 5.40 billion, a decrease of -35.49%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to one analyst, the rating for SNY stock is "Hold" and the 12-month stock price forecast is $55.0.
News
Sanofi eyes German insulin investment of up to $1.6 bln, source says
French drugmaker Sanofi is nearing a decision to invest between 1.3 billion and 1.5 billion euros ($1.4-$1.6 billion) to upgrade its production of long-acting insulin shots in Germany, a person famili...
Sanofi eyes investment of up to $1.6 bln in Germany, Handelsblatt says
French drugmaker Sanofi is nearing a decision to invest between 1.3 billion euros and 1.5 billion euros ($1.4-$1.6 billion) at a major production site in Frankfurt, Germany, where it makes insulin bra...
German vaccine panel endorses Astra-Sanofi's RSV shot for infants
Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca and Sanofi's antibody therapy to protect them against the common respiratory infecti...
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM Majority of patients in this age group with eosinophilic esophagitis receiving Dupixen...
Sanofi-backed Formation Bio raises $372 million in late-stage funding round
AI-based drug developer Formation Bio said on Wednesday that it has raised $372 million in a late-stage funding round, with a significant participation from French drugmaker Sanofi.
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
Sanofi SA SNY is calling for initial bids for its $20 billion consumer health division.
Press Release: Availability of the Q2 2024 Aide-mémoire
Availability of the Q2 2024 Aide-mémoire Paris, France – June 25, 2024. Sanofi announced that its Q2 2024 Aide-mémoire is available on the "Investors" page of the company's website: https://www.sanofi...
Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi's Executive Committee
Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi's Executive Committee Paris, June 21, 2024. Audrey Duval Derveloy, a seasoned healthcare industry leader and Sanofi F...
Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran
ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran Seven oral presentations across the hemophilia portfolio reinforce Sanofi's commitment to bring potential first...
Belharra Therapeutics Announces Strategic Collaboration with Sanofi to Advance Discovery of Novel Small Molecule Therapeutics for Immunological Diseases
Belharra today announced a strategic collaboration with Sanofi to advance the discovery of novel small molecule therapeutics for immunological diseases.
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
Sanofi launches 2024 global Employee Stock Purchase Plan Paris, May 31, 2024. Sanofi's global employee shareholder plan, Action 2024, opens on June 4, 2024, to around 80,000 employees in 56 countries.
FDA extends deadline, requests more data on Sanofi's Dupixent for treating 'smoker's lung'
French drugmaker Sanofi and its partner Regeneron said on Friday the U.S. Food and Drug Administration (FDA) requested additional analyses on the efficacy of Dupixent as an add-on treatment in certain...
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 tria...
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation Paris and Tarrytown, NY May 31, 2024. The US Food and Drug Administration (FDA) has extended by th...
Press Release: Sanofi completes acquisition of Inhibrx, Inc.
Sanofi completes acquisition of Inhibrx, Inc. Paris, May 30, 2024. Sanofi announced today the completion of its acquisition of Inhibrx, Inc. (“Inhibrx”).
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma
Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review granted based on positive results from IMROZ phase 3 study If ...
Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million
A judge in Hawaii on Tuesday ordered Bristol Myers Squibb and Sanofi to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix, up...
Sanofi chief on new partnership with OpenAI for AI-driven drug development
Emmanuel Frenehard, Executive Vice President and Chief Digital Officer at Sanofi, discusses the company's new partnership with OpenAI and Formation Bio for AI-driven drug development.
Sanofi partners with OpenAI, Formation Bio on AI-driven drug development
French drugmaker Sanofi on Tuesday announced it is collaborating with artificial intelligence company OpenAI and Formation Bio to boost its drug development projects through the use of Artificial Inte...
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration Paris, New York, N.Y., and San Francisco, CA, May 21, 2024.
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
Dupixent ® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent sign...
Shah Capital ends campaign against Novavax board after Sanofi deal
Hedge fund Shah Capital said on Monday it would withdraw its campaign against the re-election of three directors on Novavax's board, after the COVID-19 vaccine maker struck a licensing deal with Sanof...
Novavax stock jumps 50% as Sanofi deal kicks off turning point for struggling vaccine maker
Novavax said the deal with Sanofi allows it to remove its "going concern" warning, which it first issued last year due to doubts about staying afloat.
Sanofi to Spend $1 Billion to Boost Drug Production in France
Sanofi said the bulk of the investment will double capacity of monoclonal antibody production, which are key in developing an array of pharmaceuticals, at its Vitry-sur-Seine site.